A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients - PubMed (original) (raw)
Clinical Trial
. 2007 Nov;14(11):885-93.
doi: 10.1038/sj.cgt.7701080. Epub 2007 Aug 17.
Affiliations
- PMID: 17704755
- DOI: 10.1038/sj.cgt.7701080
Clinical Trial
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
J Nemunaitis et al. Cancer Gene Ther. 2007 Nov.
Abstract
ONYX-015 is an attenuated chimeric human group C adenovirus, which preferentially replicates in and lyses tumor cells that are p53 negative. The purpose of this phase I, dose-escalation study was to determine the safety and feasibility of intravenous infusion with ONYX-015 in combination with enbrel in patients with advanced carcinoma. Enbrel is a recombinant dimer of human tumor-necrosis factor (TNF)-alpha receptor, previously shown to reduce the level of functional TNF. Nine patients, three in each cohort received multiple cycles of ONYX-015 infusion (1 x 10(10), 1 x 10(11) and 1 x 10(12) vp weekly for 4 weeks/cycle) in addition to subcutaneous enbrel (only during cycle 1) injections per FDA-indicated dosing. Of the nine patients, four had stable disease. No significant adverse events were attributed to the experimental regimen, confirming that enbrel can be safely administered along with oncolytic virotherapy. Two of the three patients in cohort 3 had detectable viral DNA at days 3 and 8 post-ONYX-015 infusion. Their detectable circulating viral DNA was markedly higher during cycle 1 (with enbrel coadministration) as compared with cycle 2 (without enbrel) at the same time points. Area under the curve determinations indicate a marked higher level of TNF-alpha induction and accelerated clearance at cycle 2 in the absence of enbrel. Further assessment is recommended.
Similar articles
- Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.
Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Deswal A, et al. Circulation. 1999 Jun 29;99(25):3224-6. doi: 10.1161/01.cir.99.25.3224. Circulation. 1999. PMID: 10385494 Clinical Trial. - Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Nemunaitis J, Cunningham C, Tong A, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S. Nemunaitis J, et al. Cancer Gene Ther. 2003 May;10(5):341-52. doi: 10.1038/sj.cgt.7700585. Cancer Gene Ther. 2003. PMID: 12719704 Clinical Trial. - A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL. Madhusudan S, et al. Clin Cancer Res. 2004 Oct 1;10(19):6528-34. doi: 10.1158/1078-0432.CCR-04-0730. Clin Cancer Res. 2004. PMID: 15475440 Clinical Trial. - Etanercept (Enbrel) -- an update.
Goffe B. Goffe B. Skin Therapy Lett. 2004 Dec-2005 Jan;9(10):1-4, 9. Skin Therapy Lett. 2004. PMID: 15657632 Review. - Adult onset Still's disease: response to Enbrel.
Asherson RA, Pascoe L. Asherson RA, et al. Ann Rheum Dis. 2002 Sep;61(9):859-60; author reply 860. doi: 10.1136/ard.61.9.859-a. Ann Rheum Dis. 2002. PMID: 12176823 Free PMC article. Review. No abstract available.
Cited by
- Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening.
Zhong Y, Le H, Zhang X, Dai Y, Guo F, Ran X, Hu G, Xie Q, Wang D, Cai Y. Zhong Y, et al. J Hematol Oncol. 2024 May 23;17(1):36. doi: 10.1186/s13045-024-01554-5. J Hematol Oncol. 2024. PMID: 38783389 Free PMC article. - Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.
Robert S, Roman Ortiz NI, LaRocca CJ, Ostrander JH, Davydova J. Robert S, et al. Viruses. 2024 Apr 5;16(4):567. doi: 10.3390/v16040567. Viruses. 2024. PMID: 38675909 Free PMC article. - New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H, Ślubowska A, Mroczek M, Borowczyk M, Braszka M, Dworacki G, Dobosz P, Wichtowski M. Chowaniec H, et al. Front Immunol. 2024 Mar 21;15:1375433. doi: 10.3389/fimmu.2024.1375433. eCollection 2024. Front Immunol. 2024. PMID: 38576614 Free PMC article. Review. - Anticancer Activity of Measles-Mumps-Rubella MMR Vaccine Viruses against Glioblastoma.
Khalid Z, Coco S, Ullah N, Pulliero A, Cortese K, Varesano S, Orsi A, Izzotti A. Khalid Z, et al. Cancers (Basel). 2023 Aug 28;15(17):4304. doi: 10.3390/cancers15174304. Cancers (Basel). 2023. PMID: 37686579 Free PMC article. - Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health.
Thoidingjam S, Sriramulu S, Freytag S, Brown SL, Kim JH, Chetty IJ, Siddiqui F, Movsas B, Nyati S. Thoidingjam S, et al. Transl Med Commun. 2023;8(1):11. doi: 10.1186/s41231-023-00144-w. Epub 2023 Apr 10. Transl Med Commun. 2023. PMID: 37065938 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous